Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the...
Learn more
Documentary: ‘The Parkinson’s Drug Trial: A Miracle Cure?’
This award winning documentary was first broadcast in 2019 and features trial participants, including our late co-founder Tom Isaacs, in a cutting-edge drug trial involving complex brain surgery; and it is hoped it will be broadcast again in 2021.
GDNF – A new chapter
We welcome the news of further investment in GDNF (Glial Cell-Line Derived Neurotrophic Factor) by Parkinson’s UK.
‘AskBio’ acquires BNB and GDNF gene therapy trials
BNB and AskBio have joined forces to expand a gene therapy programme for Parkinson’s
Herantis Pharma: Phase 1/2 CDNF topline results
We are delighted that Finnish-based Herantis Pharma Plc have announced that their ongoing phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint of safety and tolerability. In pre-clinical studies, CDNF has…
GDNF and cell transplantation: dual therapies for Parkinson’s
Parkinson’s is a complex condition and it is becoming increasingly clear that the future of disease-modifying therapies for Parkinson’s will rely on the use of multiple treatment approaches, as opposed to a single therapy. Scientists in Australia have recently published pre-clinical research exploring this idea…